{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:09:31Z","timestamp":1767704971745,"version":"3.48.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002703","name":"Jiangsu University","doi-asserted-by":"crossref","award":["JDYY2023019"],"award-info":[{"award-number":["JDYY2023019"]}],"id":[{"id":"10.13039\/501100002703","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The People's Hospital Affiliated to Jiangsu University","award":["YXJL-2002-0435-0375"],"award-info":[{"award-number":["YXJL-2002-0435-0375"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05372-8","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:59:28Z","timestamp":1765382368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors and quality of life in non-small cell lung cancer with leptomeningeal metastasis: a dichotomous pattern based on parenchymal involvement"],"prefix":"10.1007","volume":"176","author":[{"given":"Yiyao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"5372_CR1","doi-asserted-by":"publisher","unstructured":"Wang Y, Yang X, Li NJ et al (2022) Leptomeningeal metastases in non-small cell lung cancer: diagnosis and treatment. Lung cancer 174:1\u201313. https:\/\/doi.org\/10.1016\/j.lungcan.2022.09.013","DOI":"10.1016\/j.lungcan.2022.09.013"},{"key":"5372_CR2","doi-asserted-by":"publisher","unstructured":"Lee YJ, Choi HJ, Kim SK et al (2010) Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer 116:1336\u20131343. https:\/\/doi.org\/10.1002\/cncr.24877","DOI":"10.1002\/cncr.24877"},{"key":"5372_CR3","doi-asserted-by":"publisher","unstructured":"Cheng H, Perez-Soler R(2018) Leptomeningeal metastases in non-small-cell lung cancer. Lancet oncol19:e43\u2013e55. https:\/\/doi.org\/10.1016\/s1470-2045(17)30689-7","DOI":"10.1016\/s1470-2045(17)30689-7"},{"key":"5372_CR4","doi-asserted-by":"publisher","unstructured":"Le Rhun E, Devos P, Weller J et al (2021) Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. Neuro, Oncol 23:1100\u20131112. https:\/\/doi.org\/10.1093\/neuonc\/noaa298","DOI":"10.1093\/neuonc\/noaa298"},{"key":"5372_CR5","doi-asserted-by":"publisher","unstructured":"Li YS, Jiang BY, Yang JJ et al (2016) Leptomeningeal metastases in patients with NSCLC with EGFR Mutations. J thorac Oncol 11:1962\u20131969. https:\/\/doi.org\/10.1016\/j.jtho.2016.06.029","DOI":"10.1016\/j.jtho.2016.06.029"},{"key":"5372_CR6","unstructured":"Wan C, Zhang C, Tang X et al (2005) Evaluation of the Chinese version of the EORTC QLQ-C30 quality of life scale for cancer patients. J Practical Oncol 353\u2013355. https:\/\/doi.org\/Cnki:Sun:Syzz.0.2005-04-027"},{"key":"5372_CR7","doi-asserted-by":"publisher","unstructured":"Le Rhun E, Weller M, Brandsma D et al (2017) EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann oncol 28:iv84\u2013iv99. https:\/\/doi.org\/10.1093\/annonc\/mdx221","DOI":"10.1093\/annonc\/mdx221"},{"key":"5372_CR8","doi-asserted-by":"publisher","unstructured":"Yan W, Jing W, An N et al (2019) The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer Institute. Cancer Med 8:2769\u20132776. https:\/\/doi.org\/10.1002\/cam4.2156","DOI":"10.1002\/cam4.2156"},{"key":"5372_CR9","doi-asserted-by":"publisher","unstructured":"Zhang M, Tong J, Ma W et al (2022) Predictors of lung adenocarcinoma with leptomeningeal metastases: a 2022 targeted-therapy-assisted MolGPA model. Front Oncol 12:903851. https:\/\/doi.org\/10.3389\/fonc.2022.903851","DOI":"10.3389\/fonc.2022.903851"},{"key":"5372_CR10","doi-asserted-by":"publisher","unstructured":"Turner BE, Prabhu RS, Burri SH et al (2020) Nodular leptomeningeal disease-a distinct pattern of recurrence after postresection stereotactic radiosurgery for brain metastases: a multi-institutional study of interobserver reliability. Int J Radiat Oncol Biol Phys 106:579\u2013586. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.10.002","DOI":"10.1016\/j.ijrobp.2019.10.002"},{"key":"5372_CR11","doi-asserted-by":"publisher","unstructured":"Oechsle K, Lange-Brock V, Kruell A et al (2010) Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol 136:1729\u20131735. https:\/\/doi.org\/10.1007\/s00432-010-0831-x","DOI":"10.1007\/s00432-010-0831-x"},{"key":"5372_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.lungcan.2011.11.022","volume":"76","author":"JH Park","year":"2012","unstructured":"Park JH, Kim YJ, Lee JO et al (2012) Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 76:387\u2013392. https:\/\/doi.org\/10.1016\/j.lungcan.2011.11.022","journal-title":"Lung Cancer"},{"key":"5372_CR13","doi-asserted-by":"publisher","unstructured":"Hyun JW, Jeong IH, Joung A et al (2016) Leptomeningeal metastasis: clinical experience of 519 cases. Eur J Cancer 56:107\u2013114. https:\/\/doi.org\/10.1016\/j.ejca.2015.12.021","DOI":"10.1016\/j.ejca.2015.12.021"},{"key":"5372_CR14","doi-asserted-by":"publisher","unstructured":"Goyal G, Singh A, Avaronnan M et al (2024) Treatment pattern and outcomes of leptomeningeal carcinomatosis in India - a retrospective study. Lancet reg health Southeast Asia 24:100331. https:\/\/doi.org\/10.1016\/j.lansea.2023.100331","DOI":"10.1016\/j.lansea.2023.100331"},{"key":"5372_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13014-020-01627-y","volume":"15","author":"J Zhen","year":"2020","unstructured":"Zhen J, Wen L, Lai M et al (2020) Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study. Radiat Oncol 15:185. https:\/\/doi.org\/10.1186\/s13014-020-01627-y","journal-title":"Radiat Oncol"},{"key":"5372_CR16","doi-asserted-by":"publisher","unstructured":"Besse B, Le Moulec S, Mazi\u00e8res J et al (2015) Bevacizumab in patients with nonsquamous Non-Small cell lung cancer and Asymptomatic, untreated brain metastases (BRAIN): A Nonrandomized, phase II Study. Clin cancer res 21:1896\u20131903. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2082","DOI":"10.1158\/1078-0432.Ccr-14-2082"},{"key":"5372_CR17","doi-asserted-by":"publisher","unstructured":"Gubens MA, Chuang JC, Akerley W et al (2018) A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. J Thorac Dis 10:219\u2013227. https:\/\/doi.org\/10.21037\/jtd.2017.12.30","DOI":"10.21037\/jtd.2017.12.30"},{"key":"5372_CR18","doi-asserted-by":"publisher","unstructured":"Jiang S, Liang H, Liu Z et al (2020) The impact of anlotinib on brain metastases of non-small cell lung cancer: post hoc analysis of a phase III randomized control trial (ALTER0303).Oncologist 25:e870\u2013e874. https:\/\/doi.org\/10.1634\/theoncologist.2019-0838","DOI":"10.1634\/theoncologist.2019-0838"},{"key":"5372_CR19","doi-asserted-by":"publisher","unstructured":"Zhou Q, Xu CR, Cheng Y et al (2021) Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study. Cancer Cell 39:1279\u20131291.e1273. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.005","DOI":"10.1016\/j.ccell.2021.07.005"},{"key":"5372_CR20","doi-asserted-by":"publisher","unstructured":"Fang W, Zhao Y, Luo Y et al (2024) Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial. Jama 332:561\u2013570. https:\/\/doi.org\/10.1001\/jama.2024.10613","DOI":"10.1001\/jama.2024.10613"},{"key":"5372_CR21","doi-asserted-by":"publisher","unstructured":"Lin G, Wang Y, Xin T et al (2025) Chinese expert consensus on leptomeningeal metastases of lung cancer. Thorac cancer 16:e70088. https:\/\/doi.org\/10.1111\/1759-7714.70088","DOI":"10.1111\/1759-7714.70088"},{"key":"5372_CR22","doi-asserted-by":"publisher","unstructured":"Wu Y, Zhao Y, Wu Y et al (2024) A retrospective Real-World study of prognostic factors associated with EGFR mutated lung cancer with leptomeningeal metastasis. Clin Lung Cancer 25:347\u2013353e341. https:\/\/doi.org\/10.1016\/j.cllc.2024.02.001","DOI":"10.1016\/j.cllc.2024.02.001"},{"key":"5372_CR23","doi-asserted-by":"publisher","unstructured":"Fang L, Zhao W, Ye B et al (2021) Combination of immune checkpoint inhibitors and Anti-Angiogenic agents in brain metastases from Non-Small cell lung cancer. Front Oncol 11:670313. https:\/\/doi.org\/10.3389\/fonc.2021.670313","DOI":"10.3389\/fonc.2021.670313"},{"key":"5372_CR24","doi-asserted-by":"publisher","unstructured":"Russo A, Russano M, Franchina T et al (2020) Neutrophil-to-Lymphocyte ratio (NLR), Platelet-to-Lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated Non-Small cell lung cancer (NSCLC): A large retrospective multicenter Study. Adv ther 37:1145\u20131155. https:\/\/doi.org\/10.1007\/s12325-020-01229-w","DOI":"10.1007\/s12325-020-01229-w"},{"key":"5372_CR25","doi-asserted-by":"publisher","unstructured":"Zhang N, Jiang J, Tang S et al (2020) Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Int Immunopharmacol 85:106677. https:\/\/doi.org\/10.1016\/j.intimp.2020.106677","DOI":"10.1016\/j.intimp.2020.106677"},{"key":"5372_CR26","doi-asserted-by":"publisher","unstructured":"Huang Y, Zhu L, Guo T et al (2021) Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis. Hum Vaccin Immunother 17:1278\u20131287. https:\/\/doi.org\/10.1080\/21645515.2020.1823779","DOI":"10.1080\/21645515.2020.1823779"},{"key":"5372_CR27","doi-asserted-by":"publisher","unstructured":"Gwak HS, Joo J, Kim S et al (2013) Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol 8:599\u2013605. https:\/\/doi.org\/10.1097\/JTO.0b013e318287c943","DOI":"10.1097\/JTO.0b013e318287c943"},{"key":"5372_CR28","doi-asserted-by":"publisher","unstructured":"Flippot R, Biondani P, Auclin E et al (2019) Activity of EGFR tyrosine kinase inhibitors in NSCLC with refractory leptomeningeal Metastases. J thorac oncol 14:1400\u20131407. https:\/\/doi.org\/10.1016\/j.jtho.2019.05.007","DOI":"10.1016\/j.jtho.2019.05.007"},{"key":"5372_CR29","doi-asserted-by":"publisher","unstructured":"Kim J, Choi H, Lee YH et al (2022) Response to Amivantamab, a bispecific EGF and MET receptor directed Antibody, in a patient with an atypical EGFR mutated (G719X) Non-Small cell lung cancer (NSCLC) with leptomeningeal disease who progressed on osimertinib. Cancer Research 82. https:\/\/doi.org\/10.1158\/1538-7445.am2022-4113","DOI":"10.1158\/1538-7445.am2022-4113"},{"key":"5372_CR30","doi-asserted-by":"publisher","unstructured":"Pareek V, Welch M, Ravera E et al (2016) Marked differences in CNS activity among EGFR inhibitors: case report and Mini-Review. Journal of Thoracic Oncology 11. https:\/\/doi.org\/10.1016\/j.jtho.2016.07.010","DOI":"10.1016\/j.jtho.2016.07.010"},{"key":"5372_CR31","doi-asserted-by":"publisher","unstructured":"Lee J, Ku BM, Shim JH et al (2019) P2.14-54 high incidence of CNS metastases in advanced or recurrent non-small cell lung cancer patients with RET Fusion. Journal of Thoracic Oncology 14. https:\/\/doi.org\/10.1016\/j.jtho.2019.08.1839","DOI":"10.1016\/j.jtho.2019.08.1839"},{"key":"5372_CR32","doi-asserted-by":"publisher","unstructured":"Wang T, Chen J, Yang J et al (2022) CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis. Transl Breast Cancer Res 3:22. https:\/\/doi.org\/10.21037\/tbcr-22-30","DOI":"10.21037\/tbcr-22-30"},{"key":"5372_CR33","doi-asserted-by":"publisher","unstructured":"Wang XS, Zhao F, Fisch MJ et al (2014) Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors. Cancer 120:425\u2013432. https:\/\/doi.org\/10.1002\/cncr.28434","DOI":"10.1002\/cncr.28434"},{"key":"5372_CR34","doi-asserted-by":"publisher","unstructured":"Bower JE, Bak K, Berger A et al (2014) Screening, assessment, and management of fatigue in adult survivors of cancer: an American society of clinical oncology clinical practice guideline adaptation. J Clin Oncol 32:1840\u20131850. https:\/\/doi.org\/10.1200\/jco.2013.53.4495","DOI":"10.1200\/jco.2013.53.4495"},{"key":"5372_CR35","doi-asserted-by":"publisher","unstructured":"Berger AM, Mooney K, Alvarez-Perez A et al (2015) Cancer-Related Fatigue, version 2.2015. J Natl Compr Canc Netw 13:1012\u20131039. https:\/\/doi.org\/10.6004\/jnccn.2015.0122","DOI":"10.6004\/jnccn.2015.0122"},{"key":"5372_CR36","doi-asserted-by":"publisher","unstructured":"Temel JS, Greer JA, Muzikansky A et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733\u2013742. https:\/\/doi.org\/10.1056\/NEJMoa1000678","DOI":"10.1056\/NEJMoa1000678"},{"key":"5372_CR37","doi-asserted-by":"publisher","unstructured":"Hsiao F-H, Lin Z-Z, Huang F-Y et al (2022) The Long-Term and mediating effects of mindfulness integrated with body-mind-spirit group therapy on depressive symptoms and quality of life among non-small cell lung cancer patients. Mindfulness 13:351\u2013361. https:\/\/doi.org\/10.1007\/s12671-021-01793-4","DOI":"10.1007\/s12671-021-01793-4"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05372-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05372-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05372-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:34:57Z","timestamp":1767702897000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05372-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5372"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05372-8","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"type":"print","value":"0167-594X"},{"type":"electronic","value":"1573-7373"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"25 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study has been approved by the Ethics Review Board of The People\u2019s Hospital Affiliated to Jiangsu University (SQK-2025127-W), and it conforms to the provisions of the Declaration of Helsinki. Owing to the retrospective nature of the study, the requirement for informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}